Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis

Abstract The clinical data on the biologic disease-modifying antirheumatic drug (bDMARD) use in late-onset ankylosing spondylitis (LOAS) is limited. Thus, this study aimed to evaluate the drug efficacy and retention rate of bDMARDs in LOAS and compare it to young-onset ankylosing spondylitis (YOAS)....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Se Hee Kim, Hae-Rim Kim, Sang-Heon Lee, Kichul Shin, Hyoun-Ah Kim, Hong Ki Min
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2394faec976d44bc8e71473bf6d4cc53
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2394faec976d44bc8e71473bf6d4cc53
record_format	dspace
spelling	oai:doaj.org-article:2394faec976d44bc8e71473bf6d4cc532021-11-08T10:52:56ZEffectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis10.1038/s41598-021-01132-62045-2322https://doaj.org/article/2394faec976d44bc8e71473bf6d4cc532021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01132-6https://doaj.org/toc/2045-2322Abstract The clinical data on the biologic disease-modifying antirheumatic drug (bDMARD) use in late-onset ankylosing spondylitis (LOAS) is limited. Thus, this study aimed to evaluate the drug efficacy and retention rate of bDMARDs in LOAS and compare it to young-onset ankylosing spondylitis (YOAS). Data of patients with AS receiving bDMARDs were extracted from the Korean College of Rheumatology Biologics and Targeted Therapy registry. Patients whose age of onset was > 50 years and ≤ 50 years were classified as having LOAS and YOAS, respectively. Their baseline characteristics and disease-associated parameters were evaluated. Drug efficacy [Ankylosing Spondylitis Disease Activity Score (ASDAS)-clinically important improvement (CII), ASDAS-major improvement (MI), Assessment of SpondyloArthritis International Society (ASAS) 20, and ASAS 40] at 1-year follow-up and drug retention rates were assessed. A total of 1708 patients (comprising 1472 patients with YOAS and 236 patients with LOAS) were included in this analysis. The LOAS group had a lower prevalence among males, lower HLA-B27 positivity and a higher prevalence of peripheral arthritis. Patients with LOAS were more likely to have higher disease-associated parameters (inflammatory reactants, patient global assessment, ASDAS-erythrocyte sedimentation rate, and ASDAS-C-reactive protein). LOAS was negatively associated with achieving ASDAS-CII, ASAS 20, and ASAS 40. The drug retention rate was lower in LOAS; however, the propensity score-matched and covariate-adjusted hazard ratios for bDMARD discontinuation were comparable to YOAS. There were no differences in the drug retention rates based on the type of bDMARD used in LOAS. Inferior clinical efficacy and shorter drug retention time were found in patients with LOAS receiving bDMARDs using real-world nationwide data. There were no differences among each bDMARD type.Se Hee KimHae-Rim KimSang-Heon LeeKichul ShinHyoun-Ah KimHong Ki MinNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Se Hee Kim Hae-Rim Kim Sang-Heon Lee Kichul Shin Hyoun-Ah Kim Hong Ki Min Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis
description	Abstract The clinical data on the biologic disease-modifying antirheumatic drug (bDMARD) use in late-onset ankylosing spondylitis (LOAS) is limited. Thus, this study aimed to evaluate the drug efficacy and retention rate of bDMARDs in LOAS and compare it to young-onset ankylosing spondylitis (YOAS). Data of patients with AS receiving bDMARDs were extracted from the Korean College of Rheumatology Biologics and Targeted Therapy registry. Patients whose age of onset was > 50 years and ≤ 50 years were classified as having LOAS and YOAS, respectively. Their baseline characteristics and disease-associated parameters were evaluated. Drug efficacy [Ankylosing Spondylitis Disease Activity Score (ASDAS)-clinically important improvement (CII), ASDAS-major improvement (MI), Assessment of SpondyloArthritis International Society (ASAS) 20, and ASAS 40] at 1-year follow-up and drug retention rates were assessed. A total of 1708 patients (comprising 1472 patients with YOAS and 236 patients with LOAS) were included in this analysis. The LOAS group had a lower prevalence among males, lower HLA-B27 positivity and a higher prevalence of peripheral arthritis. Patients with LOAS were more likely to have higher disease-associated parameters (inflammatory reactants, patient global assessment, ASDAS-erythrocyte sedimentation rate, and ASDAS-C-reactive protein). LOAS was negatively associated with achieving ASDAS-CII, ASAS 20, and ASAS 40. The drug retention rate was lower in LOAS; however, the propensity score-matched and covariate-adjusted hazard ratios for bDMARD discontinuation were comparable to YOAS. There were no differences in the drug retention rates based on the type of bDMARD used in LOAS. Inferior clinical efficacy and shorter drug retention time were found in patients with LOAS receiving bDMARDs using real-world nationwide data. There were no differences among each bDMARD type.
format	article
author	Se Hee Kim Hae-Rim Kim Sang-Heon Lee Kichul Shin Hyoun-Ah Kim Hong Ki Min
author_facet	Se Hee Kim Hae-Rim Kim Sang-Heon Lee Kichul Shin Hyoun-Ah Kim Hong Ki Min
author_sort	Se Hee Kim
title	Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis
title_short	Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis
title_full	Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis
title_fullStr	Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis
title_full_unstemmed	Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis
title_sort	effectiveness and drug retention of biologic disease modifying antirheumatic drugs in korean patients with late onset ankylosing spondylitis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2394faec976d44bc8e71473bf6d4cc53
work_keys_str_mv	AT seheekim effectivenessanddrugretentionofbiologicdiseasemodifyingantirheumaticdrugsinkoreanpatientswithlateonsetankylosingspondylitis AT haerimkim effectivenessanddrugretentionofbiologicdiseasemodifyingantirheumaticdrugsinkoreanpatientswithlateonsetankylosingspondylitis AT sangheonlee effectivenessanddrugretentionofbiologicdiseasemodifyingantirheumaticdrugsinkoreanpatientswithlateonsetankylosingspondylitis AT kichulshin effectivenessanddrugretentionofbiologicdiseasemodifyingantirheumaticdrugsinkoreanpatientswithlateonsetankylosingspondylitis AT hyounahkim effectivenessanddrugretentionofbiologicdiseasemodifyingantirheumaticdrugsinkoreanpatientswithlateonsetankylosingspondylitis AT hongkimin effectivenessanddrugretentionofbiologicdiseasemodifyingantirheumaticdrugsinkoreanpatientswithlateonsetankylosingspondylitis
_version_	1718442503220232192

Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis

Ejemplares similares